丹诺医药冲刺港股：9个月亏损1.15亿，估值20亿

Core Viewpoint - Danno Pharmaceuticals (Suzhou) Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, having updated its prospectus recently [1]. Financing and Valuation - Danno Pharmaceuticals has undergone multiple financing rounds since its establishment, with significant amounts raised in recent years. The D round raised approximately 148.25 million RMB with a post-money valuation of 1.648 billion RMB, while the D+ round raised 63.60 million RMB with a post-money valuation of 1.712 billion RMB. The upcoming E round is expected to raise 301.93 million RMB with a projected post-money valuation of 2.013 billion RMB [2][3]. - The per-share cost for the D, D+, and E rounds is consistently 46.32 RMB [3]. Financial Performance - The company reported no revenue since its inception, with projected R&D expenditures of 108.40 million RMB and 69.84 million RMB for 2023 and 2024, respectively. Operating losses are expected to be 122.48 million RMB and 77.99 million RMB for the same years, leading to total losses of 191.84 million RMB and 145.93 million RMB [6][7]. - For the first nine months of 2025, Danno Pharmaceuticals incurred R&D expenses of 46.40 million RMB and administrative expenses of 36.19 million RMB, resulting in an operating loss of 80.96 million RMB and a total loss of 115.46 million RMB [8]. Product Pipeline - Danno Pharmaceuticals is nearing commercialization and focuses on developing innovative drug products to address unmet clinical needs in bacterial infections and related metabolic diseases. The company has established a differentiated pipeline consisting of seven innovative assets, including three core products targeting various bacterial infections [4][5]. Cash Position - As of September 30, 2025, Danno Pharmaceuticals held cash and cash equivalents amounting to 222.10 million RMB [8]. Shareholder Structure - Major shareholders include Cumbre entities with an 18.82% stake, an employee stock ownership plan with 10.44%, AMR Action Fund entities with 7.19%, and Wuxi Fund with 6.55%. Other notable shareholders include the Chao family and various investment entities [11][14].